Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 All time
- Disclosed funding
- $19.1B 398 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| F FesariusTherapeuticsCompany profile Develops FDA-cleared hydrogel dermal regeneration templates for wound healing and reconstructive surgery Develops FDA-cleared hydrogel dermal regeneration templates for wound healing and reconstructive surgery | $20M | Series A | Biotech, Healthtech | United States | Investors | |
| A AntogenCompany profile Antogen provides immunopeptidomics services for drug discovery and translational research, identifying peptide–HLA ligands in biological samples. Antogen provides immunopeptidomics services for drug discovery and translational research, identifying peptide–HLA ligands in biological samples. | Undisclosed | Seed | Biotech | United States | Investors | |
| GM GT Medical TechnologiesCompany profile Develops bioresorbable radiotherapy implants for surgical treatment of operable brain tumors Develops bioresorbable radiotherapy implants for surgical treatment of operable brain tumors | $100M | Series ESeries C+ | Biotech, Healthtech | United States | Investors | |
| EB Element BiosciencesCompany profile Develops genomic and multiomic sequencing platforms for research, translational science, and diagnostics Develops genomic and multiomic sequencing platforms for research, translational science, and diagnostics | $175M | Series ESeries C+ | Biotech | United States | Investors | |
| RB Rejuvenate BioCompany profile Develops gene therapies for age-related and chronic diseases in animals and humans Develops gene therapies for age-related and chronic diseases in animals and humans | $6M | StrategicUndisclosed | Biotech | United States | Investors | |
| CT City TherapeuticsCompany profile City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas. City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas. | $99.5M | Series B | Biotech | United States | Investors | |
| OP Develops RNAi therapeutics for various diseases | ₩110B | StrategicUndisclosed | Biotech | South Korea | Investors | |
| ND New Dawn BioCompany profile Grows cultured wood from tree stem cells in bioreactors, eliminating the need for logging Grows cultured wood from tree stem cells in bioreactors, eliminating the need for logging | €2.1M | Pre-SeedPre-seed | Biotech, Climate tech | Netherlands | Investors | |
| AB ARTAN BioCompany profile Develops mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions Develops mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions | $200K | Seed | Biotech | United States | Investors | |
| GT Goldenrod TherapeuticsCompany profile Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways | $6.5M | Seed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.